💥EXCLUSIVE: Retsef Levi hits back after attacks on his leadership from departing CDC officials
Several top CDC officials quit in protest, denouncing @RetsefL’s leadership of the Covid vaccine work group. Now, in an exclusive interview, Levi reveals what really happened behind closed doors.
@HHS_Jim @SecKennedy @RWMaloneMD
@TheChiefNerd
Dr Demetre Daskalakis, a top official who abruptly resigned from the CDC, posted his resignation letter on @X, now viewed more than 19 million times, declaring his position at the agency “untenable.”
He pointed to the new Terms of Reference for ACIP’s Covid vaccine work group, chaired by Levi, whom he attacked as a figure of “dubious intent and more dubious scientific rigor” who had “ignored all feedback from career staff at CDC.” blog.maryannedemasi.com/p/breaking-aci… @dr_demetre
What most people don’t know is that in the weeks leading up to his resignation, @dr_demetre had been working with Levi and other members of ACIP, locked in a tense tug-of-war over how broad the work group’s remit should be.
As Chair, @RetsefL pushed for a wide lens that would follow the evidence wherever it led. Daskalakis, on the other hand, pressed to narrow the scope of the review, and sought to populate the group with CDC loyalists intent on preserving the status quo.
Senior CDC officials, opposed to Levi’s broader approach, were reluctant to sign off on the Terms of Reference.
What really happened? What went on behind closed doors between ACIP and the CDC officials who resigned?
What did CDC officials (who resigned) - want to exclude from the Covid work group's Terms of Reference?
The CDC deployed its legal team in an attempt to intimidate ACIP into excluding vital topics from the Covid work group’s Terms of Reference — issues that urgently needed examination.
.@RetsefL, for his part, is not interested in taking pot shots or fuelling a social media brawl. But he is prepared to set the record straight. Levi was calm and deliberate, weighing his words carefully — but there was steel behind them. The attack, he told me, didn’t faze him.
Please subscribe for the FULL interview 👇👇 blog.maryannedemasi.com/p/exclusive-re…
“I am just focused on the data now,” Levi said. “I’m not going to engage in personal attacks.
@Jikkyleaks @MdBreathe
@SabinehazanMD
• • •
Missing some Tweet in this thread? You can try to
force a refresh
💥FOIA documents show FDA examined reports of persistent sexual dysfunction tied to antidepressants — but declined stronger warnings
Critics say the FDA set too high an evidentiary bar before deciding against stronger warnings about persistent sexual dysfunction linked to antidepressants.
Link 👇👇
@abcsoka @PSSDNetwork @MikhailaFuller @unhealthytruth @benzosarebad @woodymatters
@jeffreytucker @Mangan150 @newstart_2024
In 2018, a citizen petition urged the FDA to update labels for SSRIs/SNRIs, warning that sexual dysfunction could continue long after discontinuation.
Years later, petitioners sued @US_FDA for failing to respond.
@DrDavidHealy @abcsoka @PssdWarrior @PSSDNetwork blog.maryannedemasi.com/p/fda-sued-for…
In light of new FOIA docs, A/Prof Csoka said he was not aware the FDA had reached any internal decision.
“If the FDA concluded that the evidence did not justify a label change, it should have said so openly, explained its reasoning, addressed the evidence submitted, and clarified what additional evidence would be needed,” said @abcsoka.
🧵 Who is steering US health policy?
@SecKennedy @HHSGov
Something unsettling is happening inside America’s health agencies. Policies shifting, meetings in limbo, decisions reversed, leadership rotating—yet it's unclear who's directing it all.
STORY LINK 👇👇
@newstart_2024 @DrEliDavid @uTobian @DowdEdward
ACIP's Feb 25 meeting was set to discuss Covid & mRNA vaccines—but Federal Register notices missed deadlines, now its up in the air.
ACIP's @RobertMaloneMD hinted at big mRNA discussions. Could that be the cause for the delay?
ACIP was already sidelined earlier this year when the childhood immunisation schedule was changed without its input. blog.maryannedemasi.com/p/america-rewr…
More ACIP issues: Recent votes on Hep B & Covid not yet updated in patient Vaccine Info Statements. Technical lag or decisions not fully implemented?
💥EXCLUSIVE: Internal documents show Paul Offit made false claims on CNN
Newly obtained emails contradict key claims made by the high-profile vaccine commentator @DrPaulOffit
.@DrPaulOffit told viewers he had not been invited to speak at the ACIP meeting that was unfolding in Atlanta at that very day. That claim was false.
I obtained exclusive records that show CDC officials had contacted him repeatedly — via emails, phone calls and a speaker-request form — inviting him to present at the upcoming meeting.
@HHS_Jim @HHSResponse
.@DrPaulOffit that before the universal birth dose, “30,000 children under the age of 10” contracted hepatitis B each year. But no such epidemic ever occurred. His figure likely stems from flawed modelling. Actual surveillance data show acute hep B cases in children under 10 were extremely low — around 400 per year — before the universal birth dose was introduced.
@HHSGov
🚨Major journal under fire for omitting Pfizer’s failed flu data in seniors
Pfizer’s mRNA flu shot failed in the over-65s, but the @NEJM never published the data — prompting calls for accountability.
STORY LINK 👇👇
@RobertKennedyJr @RetsefL
@newstart_2024 @maryhollandnyc
This week, I reported that @pfizer's mRNA flu shot offered almost no clinical benefit in adults aged 18–64 compared to a traditional flu shot. blog.maryannedemasi.com/p/pfizers-mrna…
But that was not the full story. @NEJM did not publish any data from over-65s in the same trial — the very population most at risk from influenza and the main reason these vaccines exist.
When @RetsefL discovered the missing data, he was stunned. “It seems like the reason for omitting the older participants was because the results were not favourable for the studied mRNA vaccine.”
Levi said omitting this data was “unacceptable, especially since the over-65s are among the high-risk populations that influenza vaccines aim to protect.”
Dr Eric Rubin presided over the @NEJM decision to publish a Pfizer trial that omitted vital data, allowing a reputed journal to become complicit in the same selective reporting practices that have long undermined scientific publishing.
He also sits on the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) — the same committee that may one day review Pfizer’s biological licence application for this very product.
ANALYSIS: Pfizer’s mRNA flu shot was supposed to revive confidence in the platform. Instead, its own trial results reinforce the view that mRNA is still nowhere near ready for prime time.
FULL STORY 👇👇
@RobertKennedyJr @VPrasadMDMPH
@newstart_2024 @RobSchneider
A major new trial of @pfizer's mRNA flu shot has landed — and despite flattering headlines, it is nowhere near the breakthrough the company hoped for.
The phase 3 study, published in the @NEJM
-57 cases of influenza-like illness in the mRNA group versus 87 in the comparator group (traditional flu shot, not saline placebo), producing a relative efficacy of 35%.
The absolute difference was tiny: 0.63% of the mRNA group developed symptoms compared with 0.95% of those who received the traditional vaccine.
(0.32% abs difference)
NNV: >300 people would need to be vaccinated to prevent a single mild, self-limiting illness
The trial’s primary efficacy claim came mostly from cases adjudicated by @pfizer's own central laboratory using Pfizer’s own lab assay — the same structure used in the company’s early Covid trials.
Put simply, it's a manufacturer-funded trial, written largely by Pfizer employees & finds its best efficacy in the endpoint that requires all samples to be shipped to a Pfizer-run central lab for adjudication.
@IamBrookJackson @Jikkyleaks
🚨Prozac’s dark legacy: regulators ignored early warnings of sexual harm
Internal documents show Eli Lilly and regulators buried evidence that Prozac could permanently alter sexual development.
FULL STORY 👇👇
@maryhollandnyc @ACE_CoalitionEd @Honest_Medicine
EARLY WARNINGS
A 2005 assessment by the Dutch Medicines Evaluation Board described a disturbing pattern in Eli Lilly’s own animal studies.
It found that juvenile rats exposed to fluoxetine showed delayed sexual maturation, degeneration of testicular tissue, and hormonal disruption.
They recommended against approval, concluding the benefit–risk balance was negative.
PROMISES MADE, PROMISES BROKEN
Despite significant safety concerns, in 2006, Prozac was approved for paediatric use across Europe on the condition that @EliLillyandCo use European registries to participate in long-term studies on sexual maturation.
This was to be the TADS-Jr study. But within a few years, the study was abandoned due to lack of funding.
The UK’s @MHRAgovuk accepted that “any clinical study to investigate the effects of fluoxetine on sexual maturation would be forbiddingly hard to conduct and difficult to interpret.”